Phage Treatment in Covid-19 Patients with Bacterial Co-Infections
The treatment approach will be to make phage therapy available to institutions who care for
Covid-19 patients with bacterial co-infections due to A. baumannii, P. aeruginosa or S.
aureus. Patient bacterial isolates will be tested to determine phage susceptibility prior to
and during phage therapy.
The primary objectives are to determine the feasibility of developing, producing and
providing a personalized intravenous phage for Covid-19 patients who have pneumonia,
bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus and to evaluate the
safety of intravenous phage in Covid-19 patients along with anti-microbial treatment for
pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
Other: Phage Therapy
Personalized intravenous phage therapy in Covid-19 patients along with anti-microbial treatment for pneumonia, bacteremia or septicemia due to A. baumannii, P. aeruginosa or S. aureus.
Inclusion Criteria:
- Covid-19 patients with pneumonia or bacteremia/septicemia who have culture-confirmed
bacterial co-infection with A. baumannii, P. aeruginosa or S. aureus.
- Patient provided informed and signed consent.
Exclusion Criteria:
- Patient eligible for another APT sponsored trial.
- Patient participating in another clinical trial at the same time or patients < 4 weeks
from participating in an alternative investigational protocol/study
- Patient with known allergy to infusion of phage products
- Patients with a history of Meningitis or encephalitis at time of study entry, Primary
immune deficiency disease or tuberculosis or Stroke, transient ischemic attack (TIA),
or untreated deep vein thrombosis.